Is Penumbra Inc (PEN) overvalued? · P/E 237, rev $1.19B
Penumbra Inc (PEN) is a medical devices company listed on US.
This page asks whether Penumbra Inc (PEN) looks expensive on cached numbers — not a short thesis.
Latest reported PEN revenue for 2024-12-31 was $1.19B. Net income was $14.0M. Revenue was up 319.6% from 2023-12-31 to 2024-12-31. PEN currently screens at market cap $9.93B and trailing P/E 237.4.
PEN currently screens at market cap $9.93B and trailing P/E 237.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PEN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PEN stock page for the full model, not this heading.
Not investment advice.